SpringWorks Therapeutics Company Overview
About SpringWorks Therapeutics
SpringWorks Therapeutics (NASDAQ:SWTX) is a clinical-stage biopharmaceutical entity focused on developing life-changing therapies for patients with severe rare diseases and cancer. Operating with a clear vision to leverage its deep expertise and robust pipeline, SpringWorks is ardently committed to advancing treatments for conditions where existing options are limited or non-existent. The company's projects span across a variety of drug development programs targeting critical oncology and rare disease indications, emphasizing precision medicine and innovative therapeutic approaches. With a patient-centric approach at its core, SpringWorks Therapeutics is unyielding in its mission to bring groundbreaking treatments from bench to bedside, striving to address unmet medical needs and improve outcomes for underserved patient populations.
Snapshot
Operations
Produtos e/ou serviços de SpringWorks Therapeutics
- Drug Discovery and Development: SpringWorks identifies and develops potential drug candidates through scientific research and preclinical testing.
- Clinical Trials: They conduct clinical trials in humans to evaluate the safety and efficacy of their drug candidates in various stages of development.
- Regulatory Affairs: They work with regulatory agencies like the FDA to obtain marketing approval for their drugs, allowing them to be prescribed to patients.
- Partnerships and Collaborations: SpringWorks may collaborate with other pharmaceutical companies to leverage expertise and resources for broader development and commercialization of their drugs.
- Manufacturing and Supply Chain: While not directly involved in large-scale manufacturing, they partner with other companies to ensure the quality and supply of their drugs if they reach the market.
- Commercialization: Once approved, SpringWorks may work with healthcare providers and patient advocacy groups to raise awareness and ensure access to their medications.
equipe executiva do SpringWorks Therapeutics
- Mr. Saqib Islam J.D.CEO & Director
- Mr. Francis I. Perier Jr., M.B.A.Chief Financial Officer
- Dr. Badreddin Edris Ph.D.Chief Operating Officer
- Mr. Bhavesh Ashar M.B.A.Chief Commercial Officer
- Dr. James Cassidy M.D., Ph.D.Chief Medical Officer
- Mr. Michael P. NofiChief Accounting Officer
- Mr. Tai-An Lin Ph.D.Chief Scientific Officer
- Ms. Kim DiamondVice President of Communications & Investor Relations
- Mr. Herschel S. Weinstein J.D.General Counsel & Secretary
- Mr. Daniel J. PichlChief People Officer